



Please fax this completed form to (866) 399-0929 OR mail to: Envolve Pharmacy Solutions PA Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720.

Date of request:	Reference #:		MAS:			
Patient	Date of birth		ProviderOne ID or Coordinated Care ID			
Pharmacy name	Pharmacy NPI	Telephone number		Fax number		
Prescriber	Prescriber NPI	Telephone numbe		Fax number		
Medication and strength		Dire	ections for use		Qty/Days supply	
 Is this request for a continuation of existing therapy? Yes No If yes, has patient's condition worsened? Yes. Specify reason: Viral load < 200 copies/mL Increasing CD4 cell count No What is patient's diagnosis? 						
HIV-1 Other. Specify:						
3. Is patient treatment naïve? Yes No						
 4. Does patient have Hepatitis B virus (HBV)? Yes No If yes: Is hepatic function being closely monitored? Yes No Has patient initiated an anti-HBV treatment? Yes No 						
5. What is the patient's current weight? kg Date taken:						
6. Does patient have hepatic impairment? Yes No If yes: Moderate (Child-Pugh Class B) Severe (Child-Pugh Class C) Other. Specify:						
7. What is the patient's creatinine clearance? mL/min Date taken:						
8. Will patient be using any of the following medications? (check all that apply)						
Alfusozin Dexamethaso Elbasvir Ivabradine Mitotane Phenytoin Rifampin St John's Wor	Enzalutamide Lurasidone Naloxegol Pimozide Rifapentine	į	Colchicine Dronedar Ergot Der Lomitapic Oxcarbaz PPIs Sildenafil	rone	Cisapride Elbasivir/Grazoprevir Grazoprevir Midazolam Phenobarbital Ranolazine Statins	
9. If patient is of childbearing	ng potential, does patier	it have a	confirmed r	negative pregna	ancy test? Yes No	

10. Does patient have an inability to maintain an undetectable viral load on preferred separate agents due to non-adherence?						
11. Is this prescribed by or in consultation with a specialist in infectious disease or HIV?						
Complete only for: Lamivudine/tenofovir disoproxil (Temixys):						
12. Does patient have a documented allergy to inactive ingredients contained in commercially separate agents AND Cimduo? Yes No						
Complete only for: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza):						
13. Has patient been stable on an ART regimen for at least the past 6 months with no history of treatment of treatment failure on current regimen?						
Complete only for:						
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza) Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy)						
14. Check all that apply for patient: Requires renal hemodialysis						
Hypertension	emoularysis					
Diabetes						
Hepatitis C						
African American with family history of kidney disease						
High risk for bone complications as determined by a history of:						
Arm or hip fracture with minimal trauma Vertebral compression factor						
Chronic kidney with proteinuria, low phosphate or is grade 3 or worse						
T-score ≤ -2.0 (DXA) at the femoral neck or spine						
Chronic, high-dose glucocorticoid-therapy (5 mg/day of prednisone or equivalent for at more						
than two (2) months						
What is the diagnosis requiring glucocorticoid regimen? What is not in the diagnosis requiring glucocorticoid regimen?						
 What is patient's current glucocorticoid regimen? What is the expected duration of therapy of glucocorticoid regimen? 						
what is the expected duration of therapy of glucocorticola regimen:						
CHART NOTES ARE REQUIRED WITH THIS REQUEST						
Prescriber signature	Prescriber specialty	Date				

Envolve Pharmacy Solutions will respond via fax or phone within 24 hours of receipt of the request. Requests for prior authorization must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)